ARCHER 1050, trial summary

A randomised clinical trial investigating the effect of dacomitinib versus gefitinib in Patients (pts) with newly diagnosed stage IIIB/IV/ recurrent NSCLC harboring an EGFR- activating mutation (exon 19 del or exon 21 L858R mu +/- exon 20 T790M mu)

Studied treatment	dacomitinib
Control treatment	gefitinib

Patients	Patients (pts) with newly diagnosed stage IIIB/IV/ recurrent NSCLC harboring an EGFR- activating mutation (exon 19 del or exon 21 L858R mu +/- exon 20 T790M mu)
Group sizes	-9 / -9

Blindness		Inclusion period
Follow-up duration		Centers
Lost to FU		geographical localisation
Primary endpoint	IRC PFS	Design

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:1454-1466 [PMID: 28958502] link to pdf add to Mendeley

Links

ASCO abstract

ASCO 2018 OS

ClinicalTrial.gov record NCT01774721

Registering number	NCT01774721 (see trial on clinicaltrials.gov)
Code Name